Stock Events

Stock Events

Valbiotis SA 

€0.6480
51
+€0.04+6.23%Wednesday 07:01

Statistics

Day High
0.648
Day Low
0.648
52W High
1.194
52W Low
0.534
Volume
0
Avg. Volume
0
Mkt Cap
15.36M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 12Expected
Q3 2025
Q4 2025
Q3 2026
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-1,040.55%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
905,000Revenue
-9.42MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8JD.MU. It's not an investment recommendation.
TotalEnergies
14
TTE.PA
Air Liquide
12
AI.PA
Lvmh Moet Hennessy Louis Vuitton
8
MC.PA
Sanofi
8
SAN.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk is a leading global healthcare company that develops diabetes care products, directly competing with Valbiotis' focus on metabolic diseases.
Sanofi
SNY
Mkt Cap106.24B
Sanofi is a multinational pharmaceutical company that has a strong portfolio in diabetes and cardiovascular diseases, making it a direct competitor to Valbiotis.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly is a global pharmaceutical company with significant investments in diabetes and metabolic disorders, competing in the same space as Valbiotis.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca operates in various therapeutic areas, including cardiovascular, renal, and metabolism, directly competing with Valbiotis' product offerings.
Merck
MRK
Mkt Cap368.89B
Merck is a global healthcare company with a focus on chronic diseases such as diabetes, directly competing with Valbiotis' research and development in metabolic disorders.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a global pharmaceutical corporation with a broad product portfolio that includes treatments for metabolic disorders, competing with Valbiotis.
AMGEN
AMGN
Mkt Cap251.94B
Amgen focuses on cardiovascular disease and has been expanding its portfolio in metabolic disorders, making it a competitor to Valbiotis.
Novartis
NVS
Mkt Cap303.67B
Novartis is a global healthcare company with a strong emphasis on chronic diseases, including metabolic disorders, competing with Valbiotis.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb has a diverse portfolio in cardiovascular and metabolic diseases, positioning it as a competitor to Valbiotis.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline has a focus on developing new treatments for diabetes and obesity, areas that Valbiotis is also targeting.

About

Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension. Additionally, Valbiotis is developing TOTUM-448 to treat non-alcoholic fatty liver disease. The company maintains a strategic partnership with Nestlé Health Science.
Show More
CEO
Sebastien Peltier
Employees
50
Country
France
ISIN
FR0013254851
WKN
000A2DS5F

Listings

STU
DE
8JD.STU
MU
DE
8JD.MU
F
DE
8JD.F
PA
FR
ALVAL.PA

0 Comments

Share your thoughts

FAQs

What is Valbiotis SA stock price today?▼
The current price of 8JD.MU is €0.65 EUR — it has increased by +6.23% in the past 24 hours. Watch Valbiotis SA stock price performance more closely on the chart.
What is Valbiotis SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Valbiotis SA stocks are traded under the ticker 8JD.MU.
Is Valbiotis SA stock price growing?▼
8JD.MU stock has risen by +6.23% compared to the previous week, the month change is a -1.82% fall, over the last year Valbiotis SA has showed a +10.58% increase.
What is Valbiotis SA market cap?▼
Today Valbiotis SA has the market capitalization of 15.36M
When is the next Valbiotis SA earnings date?▼
Valbiotis SA is going to release the next earnings report on March 17, 2027.
What is Valbiotis SA revenue for the last year?▼
Valbiotis SA revenue for the last year amounts to 905,000 EUR.
What is Valbiotis SA net income for the last year?▼
8JD.MU net income for the last year is -9.42M EUR.
How many employees does Valbiotis SA have?▼
As of November 6, 2026, the company has 50 employees.
In which sector is Valbiotis SA located?▼
Valbiotis SA operates in the Health & Wellness sector.
When did Valbiotis SA complete a stock split?▼
Valbiotis SA has not had any recent stock splits.
Where is Valbiotis SA headquartered?▼
Valbiotis SA is headquartered in Périgny, France.